Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMF-219 |
Synonyms | |
Therapy Description |
BMF-219, is an irreversible menin inhibitor, which potentially decreases expression of KRAS, MYC, and BCL2, and reduces tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2665; Blood (2021) 138 (Supplement 1): 4318.). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMF-219 | BMF219|BMF 219 | BMF-219, is an irreversible menin inhibitor, which potentially decreases expression of KRAS, MYC, and BCL2, and reduces tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2665; Blood (2021) 138 (Supplement 1): 4318.). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS act mut | multiple myeloma | predicted - sensitive | BMF-219 | Preclinical - Cell culture | Actionable | In a preclinical study, BMF-219 inhibited growth of multiple myeloma cell lines harboring NRAS activating mutations in culture (Cancer Res 2022;82(12_Suppl):Abstract nr 2654). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05153330 | Phase I | BMF-219 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL With KMT2A/ MLL1r, NPM1 and Other Mutations | Recruiting | USA | NLD | ITA | GRC | ESP | 0 |
NCT05631574 | Phase I | BMF-219 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer | Recruiting | USA | 1 |